Who was studied, and how
Two numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
Metformin+glucagon-like peptide-1 receptor agonists (GLP-1RA)
monotherapy
Probably lowered long-term blood sugar−1.50
randomisedThe trial randomly assignedassigned by chance
Metformin+dipeptidyl peptidase-4 inhibitors
monotherapy
Probably lowered long-term blood sugar−1.46
randomisedthe abstract, start to end
… (weighted mean difference [WMD] -1.50%; 95% confidence interval [CI] -2.04 to -0.96) and metformin+dipeptidyl peptidase-4 inhibitors (WMD -1.46%; 95% CI, -1.96 to -0.95) were …
← favours treatmentfavours comparator →
could be chanceChange in HbA1cMetformin+glucagon-like peptide-1 receptor agonists (GLP-1RA) vs monotherapy
−1.50−2.04 to −0.96
Change in HbA1cMetformin+dipeptidyl peptidase-4 inhibitors vs monotherapy
−1.46−1.96 to −0.95
MetforminGLP-1 receptor agonistsGlycemic control
1 / 5